Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.

ABSTRACT:

Background

After receiving a COVID-19 vaccine, most recipients want to know if they are protected from infection and for how long. Since neutralizing antibodies are a correlate of protection, we developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies from a drop of blood. The LFA is based on the principle that neutralizing antibodies block binding of the receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2).

Methods

The ability of the LFA was assessed to correctly measure neutralization of sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2 microneutralization assays. We also determined if the LFA distinguished patients with seasonal respiratory viruses from patients with COVID-19. To demonstrate the usefuln

SUBMITTER: Lake DF 

PROVIDER: S-EPMC8567411 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature